The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC ...
AstraZeneca AZN announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) for treating ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the ...
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult ...
(Alliance News) - AstraZeneca PLC on Thursday said the US Food & Drug Administration has approved its Imfinzi treatment for adults with limited-stage small cell lung cancer.
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...